Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TERT | O14746 | 3/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | GFER | P55789 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4563385 | 0.91 | TERT (0.53) | TERTKMT2ALMNACYP3A4HTT | |
| SCHEMBL6207835 | 0.89 | TERT (0.65) | TERTKMT2ACYP3A4 | |
| SCHEMBL4565717 | 0.88 | TERT (0.56) | TERTKMT2ACYP3A4 | |
| SCHEMBL8144115 | 0.86 | CA12 (0.42) | TERTRAB9AALDH1A1LMNACYP3A4 | |
| SCHEMBL4415571 | 0.81 | KDM1A (0.43) | TERTKMT2ACYP3A4 | |
| SCHEMBL6332500 | 0.79 | KMT2A (0.52) | TERTKMT2ANPC1RAB9ALMNA | |
| SCHEMBL6443282 | 0.77 | PDE5A (0.63) | TERTKMT2AALDH1A1KDM4E | |
| SCHEMBL29897708 | 0.76 | TERT (0.53) | TERTKMT2ACYP3A4 | |
| SCHEMBL6492024 | 0.76 | TERT (0.53) | TERTKMT2ACYP3A4 | |
| SCHEMBL6492020 | 0.76 | TERT (0.53) | TERTKMT2ACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0994115-B1 | Process for preparation of pyrazolo-(4,3-d)pyrimidin-7-ones and intermediates thereof | PFIZER LTD (GB) | 2005-03-02 | — | — | EP | disclosed |
| US-20030069422-A1 | Process for preparation of pyrazolo[4,3-d]pyrimidin-7-ones and intermediates thereof | DUNN PETER JAMES (GB) | 2003-04-10 | — | — | US | disclosed |
| US-20010009962-A1 | Process for preparation of pyrazolo[4,3-d]pyrimidin-7-ones and intermediates thereof | DUNN PETER JAMES (GB) | 2001-07-26 | — | — | US | disclosed |
| US-6207829-B1 | CYCLIZATION OF A CORRESPONDING PYRAZOLE COMPOUND | PFIZER INC. | 2001-03-27 | — | — | US | disclosed |
| EP-0994115-A2 | Process for preparation of pyrazolo-(4,3-d)pyrimidin-7-ones and intermediates thereof | Pfizer Limited (GB) | 2000-04-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010009962-A1 | Process for preparation of pyrazolo[4,3-d]pyrimidin-7-ones and intermediates thereof | UGT2B7, CYP3A7, TOP2B | TERT 2518/4885PKM 488/4885PABPC1 1221/4885 |
| US-20030069422-A1 | Process for preparation of pyrazolo[4,3-d]pyrimidin-7-ones and intermediates thereof | UGT2B7, CYP3A7, TOP2B | TERT 2518/4885PKM 488/4885PABPC1 1221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.